Oncodesign innovate in healthtech since 1995

Submission to Swiss authorities of the study protocol for its Phase 1b/2a clinical trial REVERT (RIPK2 for rEsistant  and adVanced mElanoma tReatmenT) with OPM-101, its RIPK2 inhibitor in advanced melanoma patients with resistance to anti-PD-1.

Retrieval by OPM of all rights to the OPM-201 program and associated patent portfolio Confirmation of the molecule's safety in healthy volunteers

OPM announces positive results of phase 1 healthy volunteers of OPM-101: strong target engagement with excellent safety profile

Oncodesign Precision Medicine and Navigo Proteins GmbH sign a strategic collaboration agreement for the research and development of new systemic radiotherapy agents

OPM obtains €5.6 million in public funding for its DEMOCRITE program dedicated to the clinical development of OPM-101 DEMOCRITE Project: Demonstrating the efficiency of OPM-101 by targeting RIPK2 in Inflammatory Bowel Disease

OPM obtains Deep Tech Development funding for its ANIMUS program

ANIMUS program: development of proprietary methods using AI to optimize molecules derived from our Nanocyclix® technology, for faster selection of drug candidates

Oncodesign Precision Medicine announces the result of its capital increase of around €2 million

OPM receives ERDF fund totalling €2.1 M for its COMETE program.

OPM announces a 6 million euros bank financing from Caisse d’Épargne Bourgogne Franche Comté, Crédit Agricole de Champagne Bourgogne and Société Générale

OPM announces positive interim results of its Phase 1 study evaluating OPM-101 in healthy volunteers

OPM went public on Euronext Growth in Paris.

Servier and OPM announce that Servier has exercised its exclusive license option for their drug candidate, an inhibitor of the LRRK2 (Leucine-Rich-Repeat Kinase 2) kinase target. A Phase 1 study in healthy volunteers, sponsored by Servier, is planned before the end of 2022.

OPM and Servier announce a strategic collaboration to discover new therapeutic targets for pancreatic cancer treatment

Oncodesign separates its business lines service and biotech including AI in 2 companies : Oncodesign Services & Oncodesign Precision Medicine

Oncodesign signed a research collaboration agreement with SEngine Precision Medicine, a precision oncology company for the discovery of a new personalized cancer treatment for aggressive and untreatable tumors.

Oncodesign signed a strategic R&D collaboration with TiumBio, specialized in rare diseases, to identify new drug candidates to treat fibrosis.

Oncodesign signed a strategic R&D collaboration with the pharmaceutical company Servier to identify a new drug candidate in order to better combat Parkinson’s disease.

Oncodesign acquired activities in metabolism, pharmacokinetics, bioanalysis and translational medicine, with more than 45 qualified employees in immunology and infectious diseases. This acquisition strengthened Oncodesign’s offering in the field of immunology and infectious diseases, as well as its capabilities in ADME, regulatory bioanalysis and biobank management.

Oncodesign launched its first clinical study with its PET (positron emission tomography) radiotracer in patients with non-small cell lung cancer. Florepizol is used to identify mutated forms of EGFR in patients with non-small cell lung cancer. Tumors with an EGFR-activating mutation may be treated with tyrosine kinase inhibitors. Relevant clinical data collected in this way are an innovative method of precision medicine for the good of the patient.

A Structuring Project for Competitiveness (PSPC) as part of the Investments for the Future Program (PIA) coordinated by Oncodesign was launched to develop and apply artificial intelligence techniques to cancer research. A missing link between target identification and patients, the OncoSNIPE® program is used to guide new drug discovery programs in precision medicine.

Oncodesign acquired the Ulis Research Center, with more than 50 highly qualified employees working in drug discovery, specifically in medicinal chemistry, biology, in vivo pharmacology and drug metabolism/pharmacokinetics. This acquisition strengthened Oncodesign’s pharmacological platform and medicinal chemistry capabilities, enabling it to leverage a performing Drug Discovery platform for its own programs and to offer integrated drug discovery services from start to finish.

In collaboration with 21 partners, Oncodesign launched a French consortium to develop new experimental models for eight oncology indications in order to improve the selection of effective diagnostic and therapeutic compounds.

Oncodesign targets kinases, a family of enzymes that play a key role in maintaining cellular homeostasis which, if disrupted, is involved in more than 400 diseases. Nanocyclix® is a proprietary medicinal chemistry technology based on the macrocyclization of small molecules to discover effective treatments for patients with unmet medical needs.

Oncodesign receives a €10 million grant for the IMAkinib® biomarker program in oncology. The French Innovation Agency OSEO is funding the 8-year collaborative project with the goal of improving cancer treatment through new specific radiotracers.

Created by Oncodesign, Pharmimage is a regional center of excellence for pharmaco-imaging aimed at assessing the effects of treatments and identifying biomarkers based on their translational efficacy for precision medicine. This complex located in Dijon, France, brings together hospitals, as well as biotechnology and pharmaceutical companies.

Oncodesign launched the C.Re.M.E.C (Experimental Cancer Models Resource Center) project, the first project approved by the Medicen competitiveness complex.

Creation by its CEO and founder Philippe Genne, in Dijon, as a pharmacology services company to select the best oncology drug candidates.